Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging Study of Arformoterol in COPD
NCT00691405Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Oct 2003
- Primary completion
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arformoterol in chronic obstructive pulmonary disease (COPD), sponsored by Sumitomo Pharma America. Started Oct 2003; status: completed.
02
Drugs
arformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00691405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00691405.